Matt Hewitt
Stock Analyst at Craig-Hallum
(2.67)
# 1,955
Out of 5,133 analysts
43
Total ratings
54.05%
Success rate
3.78%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $19.87 | +81.18% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $7.06 | +70.09% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.54 | +136.22% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $23.90 | +33.89% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $51.41 | +24.49% | 6 | Oct 31, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $188.78 | -25.84% | 3 | Jul 9, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $0.60 | +1,571.96% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $18.31 | +63.84% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $1.31 | +434.35% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $167.31 | +19.54% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.90 | +426.32% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $6.99 | +329.18% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.34 | +119,267.35% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $19.87
Upside: +81.18%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $7.06
Upside: +70.09%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.54
Upside: +136.22%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $23.90
Upside: +33.89%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $51.41
Upside: +24.49%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $188.78
Upside: -25.84%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $0.60
Upside: +1,571.96%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $18.31
Upside: +63.84%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $1.31
Upside: +434.35%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $167.31
Upside: +19.54%
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.90
Upside: +426.32%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $6.99
Upside: +329.18%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $0.34
Upside: +119,267.35%